Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$119.35 USD
-0.40 (-0.33%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $119.32 -0.03 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ZBH 119.35 -0.40(-0.33%)
Will ZBH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ZBH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZBH
Why Zimmer (ZBH) is Poised to Beat Earnings Estimates Again
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
ZBH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
Earnings Preview: Zimmer Biomet (ZBH) Q1 Earnings Expected to Decline
SYK vs ZBH: Which Stock Looks More Promising Ahead of Q1 Earnings?
Other News for ZBH
Oppenheimer Reaffirms Their Buy Rating on Zimmer Biomet Holdings (ZBH)
Voiant and Thirona announce commercial partnership for full scope services in imaging-based clinical trials for pulmonary diseases
Disrupting Data Management and E-commerce Strategies with Finch CEO, Lee Roquet
Zeus Names Chief Technology Officer
Best Practices for Developing End-to-End Cloud-Powered Medical Devices, Upcoming Webinar Hosted by Xtalks